TREATMENT OF PARKINSON'S DISEASE WITH NOVEL DOPAMINE D2 AGONIST SK&amp;F 101468

Kapoor, Ranjna; Pirtošek, Zvezdan; Frankel, J P; Stern, Gerald; Lees, Andrew J.; Bottomley, J; Haran, N. Sree

doi:10.1016/s0140-6736(89)90146-3

Cited by 21 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute, single-dose studies in Parkinson's disease demonstrated that ropinirole has a powerful dose-dependent effect comparable to L-dopa (Vidailhet et al, 1990). Ropinirole is also effective as an adjunctive therapy to L-dopa in patients with or without motor¯uctuations (Kapoor et al, 1989;Kleedorfer et al, 1991;Rascol et al, 1996). In a randomized double-blind study over 5 years the cumulative incidence of dyskinesia, regardless of L-dopa supplementation, was 20% in the ropinirole group and 45% in the L-dopa group (Rascol et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Sleep laboratory studies in periodic limb movement disorder (PLMD) patients as compared with normals and acute effects of ropinirole

Saletu

Anderer

Saletu

et al. 2001

Human Psychopharmacology

View full text Add to dashboard Cite

Periodic limb movement disorder (PLMD) occurs in a variety of sleep disorders and can cause insomnia as well as hypersomnia with daytime somnolence. The aim of this study was to investigate 12 untreated PLMD patients as compared with 12 normal controls and to measure the acute effects of 0.5 mg ropinirole (Requip((R))) - a non-ergoline dopamine agonist - as compared with placebo. In three nights (adaptation, placebo, ropinirole night) objective and subjective sleep and awakening quality were evaluated. In the target variable 'periodic leg movements per hour of sleep' (PLM/(hTST)) PLMD patients showed an increased value of 42/h (normal 0-5/h) with a greater number of arousals due to periodic leg movements (PLM) in sleep. They further demonstrated an increased number of awakenings, sleep stage S1, S4, stage shifts and decreased S2, but there were no significant differences concerning total sleep time, sleep efficiency (SE), subjective sleep quality and morning measures of mood, drive and drowsiness. However, measures of attention variability, numerical memory, fine motor activity and reaction time performance were impaired. Ropinirole 0.5 mg was shown to significantly improve the index PLM/(hTST) by 64% and arousals due to PLM, increase spontaneous arousals, REM-latency, stage 2 and stage shifts and decrease SREM. In the morning attention variability was attenuated and numerical memory augmented. Thus, ropinirole improved some sleep architecture and early morning measures of performance but specifically all PLM variables, which suggests a dopaminergic pathogenesis in PLMD. Copyright 2001 John Wiley & Sons, Ltd.

show abstract

Section: Introductionmentioning

confidence: 99%

Sleep laboratory studies in periodic limb movement disorder (PLMD) patients as compared with normals and acute effects of ropinirole

Saletu

Anderer

Saletu

et al. 2001

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Acute, single-dose studies in Parkinson's disease demonstrated that ropinirole has a powerful dose-dependent effect comparable to L-dopa [38]. Ropinirole has been shown to be effective as an adjunctive therapy to L-dopa in patients with or without motor fluctuations [39][40][41]. Rascol et al [42] reported that ropinirole and L-dopa were equally effective in early Parkinson's disease, while in more advanced Parkinson's disease L-dopa was superior.…”

Section: Introductionmentioning

confidence: 99%

Sleep Laboratory Studies in Restless Legs Syndrome Patients as Compared with Normals and Acute Effects of Ropinirole

et al. 2000

View full text Add to dashboard Cite

Although the restless legs syndrome (RLS) is a disorder with a relatively high prevalence rate (8% in Austria) and leads to insomnia and excessive daytime tiredness, there is a paucity of sleep laboratory data concerning objective and subjective sleep and awakening quality. Thus, the aim of this study was to investigate 12 untreated RLS patients as compared with 12 normal controls and subsequently measure the acute effects of 0.5 mg ropinirole (Requip^®) – a nonergoline dopamine agonist – as compared with placebo. In 3 nights (adaptation, placebo, ropinirole night) sleep induction, maintenance and architecture were measured objectively by polysomnography, subjective sleep and awakening quality were assessed by self-rating scales and visual-analog scales, and objective awakening quality was evaluated by a psychometric test battery. In polysomnography, RLS patients demonstrated, as compared with normal controls, a decreased total sleep time (TST) and sleep efficacy, increased wakefulness during the total sleep period and frequency of nocturnal awakenings, increased sleep stage S1, decreased S2 and increased stage shifts. Subjective sleep quality tended to decrease, and morning well-being, mood, affectivity and wakefulness were deteriorated. In the noopsyche, fine motor activity and reaction time performance were deteriorated. Ropinirole 0.5 mg induced, as compared with placebo, an increase in TST, sleep efficacy, S2 sleep and stage shifts. In the morning, somatic complaints increased slightly, while fine motor activity and reaction time performance improved. Our findings suggest a key-lock principle in the diagnosis/treatment of RLS and a dopaminergic mechanism in its pathogenesis, which is supported by the data on periodic leg movements during sleep and arousals of the subsequent paper.

show abstract

“…Most previous trials of ropinirole have concentrated on its use as monotherapy for treating the early stages of PD. In this indication, ropinirole was significantly more effective than placebo [1,2,11,13,14,23]. When ropinirole was administered over a period of 5 years, it was associated with a significantly lower incidence of dyskinesias (levodopa group 45 %, ropinirole group 20 %), while the activities of daily living scores were similar [18].…”

Section: Discussionmentioning

confidence: 97%